MedPath

BioCardia

BioCardia logo
🇺🇸United States
Ownership
Public
Established
1999-01-01
Employees
20
Market Cap
-
Website
http://www.biocardia.com
Introduction

BioCardia, Inc. is a clinical-stage biotherapeutic company. It engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

Clinical Trials

6

Active:1
Completed:1

Trial Phases

3 Phases

Phase 1:3
Phase 3:1
Not Applicable:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (50.0%)
Not Applicable
2 (33.3%)
Phase 3
1 (16.7%)

CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction

Not Applicable
Recruiting
Conditions
Ischemic Heart Failure
First Posted Date
2024-02-14
Last Posted Date
2024-08-06
Lead Sponsor
BioCardia, Inc.
Target Recruit Count
250
Registration Number
NCT06258447
Locations
🇺🇸

Morton Plant Hospital - BayCare, Clearwater, Florida, United States

Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells

Phase 1
Conditions
Heart Failure, Systolic
First Posted Date
2023-06-29
Last Posted Date
2024-12-24
Lead Sponsor
BioCardia, Inc.
Target Recruit Count
39
Registration Number
NCT05925608
Locations
🇺🇸

University of Florida, Gainesville, Florida, United States

AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial

Phase 1
Not yet recruiting
Conditions
ARDS, Human
First Posted Date
2022-08-08
Last Posted Date
2023-10-10
Lead Sponsor
BioCardia, Inc.
Target Recruit Count
9
Registration Number
NCT05491681

CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial

Not Applicable
Recruiting
Conditions
Chronic Myocardial Ischemia
Refractory Angina
First Posted Date
2018-03-07
Last Posted Date
2024-08-06
Lead Sponsor
BioCardia, Inc.
Target Recruit Count
343
Registration Number
NCT03455725
Locations
🇺🇸

University of Florida, Gainesville, Florida, United States

🇺🇸

University of Wisconsin Madison, Madison, Wisconsin, United States

CardiAMP™ Cell Therapy for Heart Failure Trial

Phase 3
Active, not recruiting
Conditions
Heart Failure, Systolic
First Posted Date
2015-05-08
Last Posted Date
2023-10-10
Lead Sponsor
BioCardia, Inc.
Target Recruit Count
125
Registration Number
NCT02438306
Locations
🇺🇸

Mayo Clinic, Phoenix, Arizona, United States

🇺🇸

Cedars Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Stanford Medical Center, Stanford Health Care, Palo Alto, California, United States

and more 22 locations
  • Prev
  • 1
  • 2
  • Next

News

BioCardia Seeks Japan PMDA Approval for CardiAMP Cell Therapy in Heart Failure Treatment

BioCardia submitted its CardiAMP autologous cell therapy to Japan's PMDA for clinical consultation, marking a significant step toward potential regulatory approval in the key Japanese market.

BioCardia Completes Low-Dose Cohort Enrollment in Novel CardiALLO Trial for Heart Failure Treatment

BioCardia has completed enrollment and dosing of the low-dose cohort in its CardiALLO Phase I/II trial, targeting ischemic heart failure patients with elevated markers of heart stress and inflammation.

Myocardial Infarction Therapeutics Pipeline Shows Promise with Over 45 Companies Involved

The myocardial infarction therapeutics pipeline is robust, featuring over 45 companies developing more than 50 potential drugs.

BioCardia Launches Morph DNA Steerable Introducer for Enhanced Biotherapeutic Delivery

BioCardia has commercially launched its Morph DNA steerable introducer, designed for enhanced control in biotherapeutic delivery, particularly in cell-therapy clinical trials.

BioCardia's CardiAMP Heart Failure Trial Results to be Presented at ACC 2025

BioCardia's CardiAMP HF Phase 3 trial results will be presented at the American College of Cardiology (ACC) 2025 Scientific Sessions.

Genprex's Reqorsa Shows Promise in Lung Cancer Gene Therapy; Uniphar Expands Commercialization Support

Genprex presented positive preclinical data for Reqorsa, a gene therapy targeting Ras inhibitor-resistant lung cancer, mesothelioma, and glioblastoma, showing increased TUSC2 uptake in tumor cells.

Shuttle Pharmaceuticals Initiates Phase 2 Trial of Ropidoxuridine for Glioblastoma

Shuttle Pharmaceuticals has enrolled the first patient in its Phase 2 clinical trial of ropidoxuridine for glioblastoma at the UVA Cancer Center.

BioCardia Completes Phase III Trial of CardiAMP Cell Therapy for Ischemic Heart Failure

BioCardia has completed the CardiAMP HF trial, a Phase III study assessing its autologous cell therapy for heart failure with reduced ejection fraction (HFrEF).

BioCardia Completes Phase III Trial of CardiAMP Cell Therapy for Ischemic Heart Failure

BioCardia has completed the Phase III CardiAMP HF trial, evaluating autologous cell therapy for heart failure with reduced ejection fraction (HFrEF).

BioCardia Completes Phase III Trial of CardiAMP Cell Therapy for Heart Failure

BioCardia has completed the final follow-up visit in its Phase III CardiAMP HF trial, which assesses the CardiAMP Cell Therapy System for heart failure with reduced ejection fraction (HFrEF).

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.